The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial
Abstract
BACKGROUND In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-onset long-acting β-agonist (LABA) used as reliever monotherapy reduces severe exacerbations compared with short-acting β-agonist (SABA) reliever therapy. We investigated the efficacy of combination budesonide-formoterol reliever therapy compared with maintenance budesonide plus as-needed terbutaline. METHODS We did a 52-week, open-label, parallel-group, multicentre, superiority, randomised controlled trial at 15 primary care or hospital-based clinical trials units and primary care practices in New Zealand. Participants were adults aged 18-75 years with a self-reported doctor's diagnosis of asthma who were using SABA for symptom relief with or without maintenance low to moderate doses of inhaled corticosteroids in the previous 12 weeks. We randomly assigned participants (1:1) to either reliever therapy with budesonide 200 μg-formoterol 6 μg Turbuhaler (one inhalation as needed for relief of symptoms) or maintenance budesonide 200 μg Turbuhaler (one inhalation twice daily) plus terbutaline 250 μg Turbuhaler (two inhalations as needed). Participants and investigators were not masked to group assignment; the statistician was masked for analysis of the primary outcome. Six study visits were scheduled: randomisation, and weeks 4, 16, 28, 40, and 52. The primary outcome was the number of severe exacerbations per patient per year analysed by intention to treat (severe exacerbations defined as use of systemic corticosteroids for at least 3 days because of asthma, or admission to hospital or an emergency department visit because of asthma requiring systemic corticosteroids). Safety analyses included all participants who had received at least one dose of study treatment. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12616000377437. FINDINGS Between May 4, 2016, and Dec 22, 2017, we assigned 890 participants to treatment and included 885 eligible participants in the analysis: 437 assigned to budesonide-formoterol as needed and 448 to budesonide maintenance plus terbutaline as needed. Severe exacerbations per patient per year were lower with as-needed budesonide-formoterol than with maintenance budesonide plus terbutaline as needed (absolute rate per patient per year 0·119 vs 0·172; relative rate 0·69, 95% CI 0·48-1·00; p=0·049). Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide-formoterol and 144 (32%) of 448 receiving maintenance budesonide plus terbutaline as needed. INTERPRETATION In adults with mild to moderate asthma, budesonide-formoterol used as needed for symptom relief was more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline. The findings support the 2019 Global Initiative for Asthma recommendation that inhaled corticosteroid-formoterol reliever therapy is an alternative regimen to daily low-dose inhaled corticosteroid for patients with mild asthma. FUNDING Health Research Council of New Zealand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Self-citationAfter asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationJuniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.08.012 · Cited by 998
Rabe, K. F., Adachi, M., Lai, C. K. W., Soriano, J. B., Vermeire, P. A., Weiss, K. B., & Weiss, S. T. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.04.042 · Cited by 943
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma: The OPTIMA Randomized Trial
O'BYRNE, P. M., BARNES, P. J., RODRIGUEZ-ROISIN, R., RUNNERSTROM, E., SANDSTROM, T., SVENSSON, K., & TATTERSFIELD, A. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.8.2104102 · Cited by 680
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Self-citationPrice, D., Fletcher, M., & van der Molen, T. (2014) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2014.9 · Cited by 554
Cited by
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Self-citationGlobal Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Self-citationImproving lung health in low-income and middle-income countries: from challenges to solutions
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C. E., Bush, A., Celli, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00458-x · Cited by 470
Self-citationKey recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L.-P., Brightling, C., Buhl, R., Brusselle, G., Cruz, A. A., Drazen, J. M., Duijts, L., et al. (2023) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-023-00330-1 · Cited by 361
Self-citationOptimal Asthma Control: Time for a New Target
Beasley, R., Braithwaite, I., Semprini, A., Kearns, C., Weatherall, M., & Pavord, I. D. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1934ci · Cited by 55
Self-citation
Metadata
- Authors
- Hardy, J., Baggott, C., Fingleton, J., Reddel, H. K., Hancox, R. J., Harwood, M., Corin, A., Sparks, J., Hall, D., Sabbagh, D., Mane, S., Vohlidkova, A., Martindale, J., Williams, M., Shirtcliffe, P., Holliday, M., Weatherall, M., Beasley, R., Corin, A., Dronfield, L., Helm, C., Paterson, T., Poudel, B., Dyer, M., Jasinski, C., Sheahan, D., Sheahan, P., Gailer, N., Van Zuilen, J., Basa, A., Devereaux, C., Egan, K., Haughey, S., Marks, R., Venter, D., Zhang, H., Trevithick, K., Williams, M., Williams, P., Baggott, C., Beasley, R., Braithwaite, I., Eathorne, A., Ebmeier, S., Fingleton, J., Hall, D., Hardy, J., Harwood, M., Holliday, M., Houghton, C., Mane, S., Martindale, J., Oldfield, K., Pilcher, J., Sabbagh, D., Shirtcliffe, P., Snively, S., Sparks, J., Vohlidkova, A., Williams, M., Collins, P., Hassan, S., Lam, A., Lionnet, C., Montgomery, B., Smaill, L., Moon, S., Quinn, D., Bayly-McCredie, E., Millar-Coote, C., Millar-Coote, D., Reid, J., Samuel, A., Burton, N., Mullard, T., Tranquilino, T., Watson, E., Bell, J., Harris, R., Richmond, J., Smith, S., Krivan, B., Robertson, C., Hancox, R. J., Weatherall, M., Glensor, S., O'Connor, D., Porrachia, A.-C., & Reddel, H. K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 394
- Issue
- 10202
- Pages
- 919-928
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2969375889
- Cited by
- 280
- References
- 23
- FWCI
- 22.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31948-8
- The paper
- Hardy, J., Baggott, C., Fingleton, J., Reddel, H. K., Hancox, R. J., Harwood, M., Corin, A., Sparks, J., Hall, D., Sabbagh, D., Mane, S., Vohlidkova, A., Martindale, J., Williams, M., Shirtcliffe, P., Holliday, M., Weatherall, M., Beasley, R., Corin, A., . . . Reddel, H. K. (2019). Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31948-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.